TY - JOUR
T1 - Pancreatic cancer associated with obesity and diabetes
T2 - An alternative approach for its targeting
AU - Pothuraju, Ramesh
AU - Rachagani, Satyanarayana
AU - Junker, Wade M.
AU - Chaudhary, Sanjib
AU - Saraswathi, Viswanathan
AU - Kaur, Sukhwinder
AU - Batra, Surinder K.
N1 - Funding Information:
The authors on this manuscript were supported, in part, by grants from the NIH [RO1 CA210637, RO1CA206444, and RO1 CA183459, UO1 CA200466, P50 CA127297 and PO1 CA217798].
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/19
Y1 - 2018/12/19
N2 - Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM). Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and development remains obscure. Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines, inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by different molecular mechanisms. Deep understanding of these factors and causal relationship between factors and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor progression. Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.
AB - Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM). Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and development remains obscure. Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines, inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by different molecular mechanisms. Deep understanding of these factors and causal relationship between factors and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor progression. Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.
KW - Adiponectin
KW - Diabetes
KW - Gut microbiota
KW - Inflammation
KW - Insulin resistance
KW - Leptin
KW - Obesity
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85058891058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058891058&partnerID=8YFLogxK
U2 - 10.1186/s13046-018-0963-4
DO - 10.1186/s13046-018-0963-4
M3 - Review article
C2 - 30567565
AN - SCOPUS:85058891058
VL - 37
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
SN - 0392-9078
IS - 1
M1 - 319
ER -